Yahoo · Oct 15, 2026
CSPC Pharmaceutical Group (SEHK:1093) Reports Encouraging SYS6002 Data, Is The Valuation Gap Still Open?
CSPC Pharmaceutical Group (SEHK:1093) has drawn fresh attention after presenting Phase I data for its Nectin-4 targeted antibody drug conjugate SYS6002 in advanced cervical cancer at IGCS2026, covering safety, tolerability and early response metrics. CSPC Pharmaceutical Group shares now trade at HK$8.865, with a 90 day share price return of 9.44% and a year to date share price gain of 4.54%. The 1 year total shareholder return is slightly down 0.73% despite a strong 76.74% total shareholder...


